[go: up one dir, main page]

AR009425A1 - Uso de creatina en la preparacion de un farmaco para el tratamiento de insuficiencias cardiacas y/o respiratorias - Google Patents

Uso de creatina en la preparacion de un farmaco para el tratamiento de insuficiencias cardiacas y/o respiratorias

Info

Publication number
AR009425A1
AR009425A1 ARP970105291A ARP970105291A AR009425A1 AR 009425 A1 AR009425 A1 AR 009425A1 AR P970105291 A ARP970105291 A AR P970105291A AR P970105291 A ARP970105291 A AR P970105291A AR 009425 A1 AR009425 A1 AR 009425A1
Authority
AR
Argentina
Prior art keywords
drug
creatine
preparation
treatment
heart
Prior art date
Application number
ARP970105291A
Other languages
English (en)
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11375243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR009425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AR009425A1 publication Critical patent/AR009425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Uso de creatina en la preparacion de un fármaco para el tratamiento de insuficiencias cardíacas y/o respiratorias. La dosis de creatina oscilaráentre 1 y 4 g/día. En particular se ha descubierto que el uso de creatina bajo las dosismencionadas fue extremadamente beneficioso a los fines de lapreparacion de un fármaco para el tratamiento de broncopatías obstructivas en un estado avanzado. La administracion del fármaco puede ser obtenido a travésde técnicas farmacéuticascomunes y comprend er además de un vehículo y/o un diluyente farmacéuticamente aceptable, uno o más ingredientes adictivos, porejemplo aminoácidos, como arginina, valina, leucina e isoleucina, azucares complejos y/o antioxidantes.
ARP970105291A 1996-11-19 1997-11-13 Uso de creatina en la preparacion de un farmaco para el tratamiento de insuficiencias cardiacas y/o respiratorias AR009425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI002408A IT1298420B1 (it) 1996-11-19 1996-11-19 Uso della creatina nell'insufficienza cardio-respiratoria

Publications (1)

Publication Number Publication Date
AR009425A1 true AR009425A1 (es) 2000-04-12

Family

ID=11375243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105291A AR009425A1 (es) 1996-11-19 1997-11-13 Uso de creatina en la preparacion de un farmaco para el tratamiento de insuficiencias cardiacas y/o respiratorias

Country Status (13)

Country Link
US (1) US6242490B1 (es)
EP (1) EP0941081B1 (es)
CN (2) CN1623534A (es)
AR (1) AR009425A1 (es)
AT (1) ATE230983T1 (es)
BR (1) BR9713514A (es)
DE (1) DE69718506T2 (es)
DK (1) DK0941081T3 (es)
ES (1) ES2191206T3 (es)
IT (1) IT1298420B1 (es)
PT (1) PT941081E (es)
RU (1) RU2202345C2 (es)
WO (1) WO1998022099A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3384539B2 (ja) * 1997-09-05 2003-03-10 義之 内田 喘息治療剤
EP1051914A1 (de) * 1999-05-08 2000-11-15 DSM Fine Chemicals Austria GmbH Verwendung von Kreatin als Futterzusatz
US9833427B2 (en) * 2000-09-14 2017-12-05 Board Of Regents Of The University Of Nebraska Creatine ester anti-inflammatory compounds and formulations
US20030212130A1 (en) * 2000-09-14 2003-11-13 Miller Donald W. Creatine ester anti-inflammatory compounds and formulations
US20030212136A1 (en) * 2001-09-14 2003-11-13 Vennerstrom Jonathan L. Creatine ester pronutrient compounds and formulations
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
US20080160086A1 (en) * 2004-02-19 2008-07-03 Scepter Holdings, Inc. Delivery Systems For Calcium
US20060025475A1 (en) * 2004-07-29 2006-02-02 Stanley Antosh Use of methyl pyruvate for the purpose of increasing muscle energy production.
US20060052448A1 (en) * 2004-09-04 2006-03-09 Mr. Stanley Antosh Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244534B1 (es) 1973-06-27 1977-07-01 Biotherax Lab
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
AU3086897A (en) 1996-06-28 1998-01-21 Ipr-Institute For Pharmaceutical Research Ag Drug preparations, containing creatine with at least one salt of calcium, magnesium, manganese or zinc

Also Published As

Publication number Publication date
EP0941081B1 (en) 2003-01-15
WO1998022099A3 (en) 1998-07-09
EP0941081A2 (en) 1999-09-15
ES2191206T3 (es) 2003-09-01
DK0941081T3 (da) 2003-04-22
US6242490B1 (en) 2001-06-05
PT941081E (pt) 2003-04-30
WO1998022099A2 (en) 1998-05-28
IT1298420B1 (it) 2000-01-05
ITMI962408A1 (it) 1998-05-19
ITMI962408A0 (it) 1996-11-19
CN1623534A (zh) 2005-06-08
BR9713514A (pt) 2000-02-29
RU2202345C2 (ru) 2003-04-20
DE69718506D1 (de) 2003-02-20
DE69718506T2 (de) 2003-07-31
ATE230983T1 (de) 2003-02-15
CN1237904A (zh) 1999-12-08

Similar Documents

Publication Publication Date Title
CA2618256C (en) Modulation of cell fates and activities by phthalazinediones
DE59509518D1 (de) Formulierung zur inhalativen applikation
AR002261A1 (es) Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio
AR013612A1 (es) Colostrinina y usos de la misma para la manufactura de un medicamento, una composicion farmaceutica que la comprende, uso de la misma como suplemento dedieta, un suplemento de dieta, un nonapeptido, el uso del mismo para la manufactura de un medicamento, composicion farmaceutica y metodo para prepar
CU22774A3 (es) Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen
FI893783A0 (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
AR009425A1 (es) Uso de creatina en la preparacion de un farmaco para el tratamiento de insuficiencias cardiacas y/o respiratorias
OA12806A (en) Novel perindopril salt and pharmaceutical compositions containing same.
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
WO2019136306A8 (en) Intranasal delivery of levodopa powder by precision olfactory device
EP0210574A3 (en) N-substituted 5-nitro anthranilic acids, process for their preparation, their use and pharmaceutical compositions based on these compounds
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
ES2144418T3 (es) Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
AU6756287A (en) Nicorandil-containing preparation for injection
ES2220256T1 (es) Albumina humana terapeutica con baja actividad para la fijacion de aluminio.
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
CA2255856A1 (en) Therapeutic uses for an aminosterol compound
DE3361591D1 (en) Polypeptides with an antagonistic activity on substance p, process for their preparation, their use and process for the purification of polypeptides
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
FR2236488B1 (es)
US3146166A (en) Cobalamin and amino acid compositions
Uebel et al. Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes

Legal Events

Date Code Title Description
FB Suspension of granting procedure